Investor Relations

Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion

JCARE Announcement on the Progress of the Proposed Public Tender of the Acquisition of Equity Interests in Vietnam’s IMP  by Controlled Subsidiary Livzon Group

Time:2025-12-30

JCARE Indicative Announcement on Acceptance of Application for Registration and Marketing Authorization for Drugs

Time:2025-12-24

JCARE Announcement on Obtaining the Approval Notice for Clinical Trial On Drug

Time:2025-12-21

JCARE Announcement on Obtaining Drug Registration Certificate for Pixavir Marboxil Capsules

Time:2025-12-11

Ad hoc announcement pursuant to Art53 LR JCARE Announcement on Inclusion of the Products in the National Reimbursement Drug List

Time:2025-12-08

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2025 Second Extraordinary General Meeting

Time:2025-11-14

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2025 Second Extraordinary General Meeting

Time:2025-10-24

Ad hoc announcement pursuant to Art. 53 LR -JCARE 2025 Third Quarterly Report

Time:2025-10-24

Ad hoc announcement pursuant to Art. 53 LR-JCARE 2025 Interim Report

Time:2025-08-22

Ad hoc announcement pursuant to Art. 53 LR-JCARE Indicative Announcement on Acceptance of Application for Registration and Marketing Authorization for Drugs

Time:2025-08-15

< 1234...14 >